United States //   Management & Directors

Management & Directors

Management & Directors

John Onopchenko

John Onopchenko became the Chief Executive Officer in May 2018 after joining us in October 2017 as Chief Operating Officer. With almost thirty years of experience in medical devices, John most recently served as Executive Vice President for Acutus Medical. In 2013, after a decade on the Board of Directors of Volcano Corporation, John stepped off the Board, joined the leadership team and ultimately became the company’s Chief Operating Officer. After Phillips acquired Volcano in March 2015, John was retained by Philips as Senior Vice President and Head of Therapy Strategy. Prior to Volcano John, was a founder and Managing Director of Synergy Life Partners, a medical device venture capital firm. The previous 20 years of John’s career included increasing leadership responsibilities at Johnson & Johnson and GE Healthcare. John received his Bachelors of Science degree from Ursinus College and his MBA from the University of Chicago.


Vaseem Mahboob joined in October 2015. Prior to joining Endologix, Mr. Mahboob served in several financial leadership positions at GE Healthcare, a worldwide leader in medical device development and distribution. His most recent role was Chief Financial Officer of their Global IT business. Prior to this position he was the Chief Financial Officer of their Eastern and African Emerging Markets where he oversaw financial operations for medical device distribution sales and service spanning 84 countries and four zones including Russia, Turkey, Middle East and Africa. Prior to this role, Mr. Mahboob was Chief Financial Officer of GE Healthcare's Global Ultrasound Business that is the most global and profitable within GE Healthcare.  Mr. Mahboob also served as CFO of GE Healthcare's Global Magnetic Resonance (MRI) Business, along with several other global financial leadership positions. Mr. Mahboob received a B.A. in Engineering from Bangalore University, and a Masters of Business Administration (MBA) in Financial Markets and Institutions & Information Systems from State University of New York, Buffalo, NY. He is also a graduate of GE's highly regarded internal corporate audit staff where he was a senior audit manager.

Matthew Thompson

Matthew Thompson, M.D., joined in December 2016. Most recently, Dr. Thompson served as Professor of Vascular Surgery at St. George's, University of London and St George's Vascular Institute (SGVI). He trained at Cambridge, St. Bartholomew's Hospital, the University of Leicester and Adelaide. His awards include a Hunterian Professorship, the Moynihan travelling fellowship and the gold medal for the intercollegiate examination. Dr. Thompson is also the editor of the Oxford Textbook of Vascular Surgery and the Oxford Handbook of Vascular Surgery. He was Chair of the National Specialized Commissioning Clinical Reference Group for Vascular Services and is a founder of the British Society for Endovascular Therapy. Dr. Thompson is also a Council Member of the Vascular Society, Chairman of the Vascular Society Annual Scientific Meeting and elected President for 2018.

Reyna Fernandez joined Endologix in January 2019 as our Chief Human Resources Officer. Reyna comes to us most recently from Canon Medical Systems, USA, where she was the Vice President, Human Resources. For five years, Reyna owned her own consulting business, where she provided strategic HR strategies, provided executive coaching and leadership development. Previously, Reyna was Vice President, Human Resources at Advanced Sterilization Products (then a J&J Company) and Director, HR for a division of ETHICON, Inc, also part of the J&J Family of Companies. She had HR leadership roles prior to J&J at Bristol Myers Squibb and Lucent Technologies. She began her work in Human Resources at Towers Watson as an HR Consultant. Reyna holds a Master’s degree in Social Administration from Columbia University and her Bachelor’s degree from Haverford College in Pennsylvania. She is a certified executive coach from the Hudson Institute, a prestigious executive coaching school in Santa Barbara.
Jeremy Hayden

Jeremy Hayden joined us in August 2017 as General Counsel. Prior to Endologix, Jeremy served as General Counsel and VP Business Development for Cytori Therapeutics, a company focused on cell therapy and nanomedicine. Prior to Cytori, Jeremy served as Assistant General Counsel for Volcano Corporation. Volcano was acquired by Royal Phillips for approximately $1.2 billion in February 2015. Prior to his tenure at Volcano, Jeremy practiced corporate and securities law at several international law firms, including Brobeck, Phleger & Harrison LLP and Mintz Levin Cohn Ferris Glovsky & Popeo, PC. Mr. Hayden received his A.B. in Politics from Princeton University and his J.D. from the University of Michigan Law School.

Jeff Brown COO web
Jeff Brown joined Endologix in August 2018 bringing twenty-four years of experience as a General Manager, Chief Operating Officer, Supply Chain Executive, Sales Leader, Consultant and Lecturer. Most recently, he was General Manager of a multi-site joint venture between Johnson & Johnson and Steris Corporation where he led significant improvements across operations, quality, engineering, and supply chain. Prior to that, he was COO of Chatham Industries, where he helped successfully orchestrate a leveraged buyout and turnaround of the firm. Prior to that, Jeff worked for five years as General Manager at Boston Scientific Corporation, where he led a critical site transformation and sat on the global supply chain management board. Jeff also worked for seven years as Worldwide Operations Manager at Johnson & Johnson and for five years leading sterilization operations across the U.S., EU, and Far East for Haemonetics Corporation. Jeff earned his MBA from Babson College in Wellesley, Massachusetts and his Bachelor of Science degree in Microbiology from the University of New Hampshire in Durham, NH.
Fecho Image

Jeff Fecho joined in June 2018. Most recently, he was the Division Vice President for Operations and New Product Quality at Abbott, where he led the global Quality organization for 20 sites and the New Product Development function. Previously, Jeff was the top Quality Officer for St. Jude Medical, where he worked for more than eleven years. At St. Jude, as Vice President, Global Quality, Jeff was responsible for the oversight, remediation, best practice propagation and the education and evangelism of quality. Jeff’s prior experience with cardiovascular products was with Boston Scientific Corporation, where he had Quality Operations and R&D positions. Jeff is an ASQ Certified Six Sigma Black Belt and received his Bachelors of Science degree in Industrial Technology from East Carolina University and his MBA from Elon College in North Carolina.

John Zehren
John Zehren joined Endologix in January 2019 as our Chief Commercial Officer. As the leader of our global sales and marketing organizations, he will be responsible for building and driving all global commercial programs and people strategies to achieve sales and profit goals across all products. Most recently John was Vice President, Sales and a senior board member for Medtronic Neurovascular, where he successfully managed their large Americas neurovascular portfolio. Prior to Medtronic, John was with Covidien and the ev3 business (each acquired by Medtronic). He worked for Edwards Lifesciences from 1997-2008 in their cardiac surgery and TMR and capital equipment businesses. John’s early positions included sales responsibilities with Pfizer Pharmaceuticals, C.R. Bard Interventional Cardiology and Carbomedics Heart Valve. John received his BA from the College of St. Thomas in St. Paul, MN in Biology and pre-med.

Michael V. Chobotov, Ph.D. joined us in February 2016 in conjunction with the merger of TriVascular.  He co-founded TriVascular as President and CEO in 1998, while creating the foundation for polymer endograft technology. He led the company’s spin-off from Boston Scientific Corporation in 2008, and continued to serve as President/CEO and member of the board of directors until 2012. Prior to co-founding TriVascular in 1998, Dr. Chobotov co-founded TransMotive Technologies, an engineering and product development consulting company. Previously, Dr. Chobotov served as Senior Vice President of R&D and board member of U.S. Electricar, and Senior Systems Engineer at Hughes Space and Communications. He also led the design of the Lunar Prospector, which was subsequently implemented as the first NASA Discovery mission. Dr. Chobotov received his Ph.D. in Mechanical Engineering, his M.S. in Mechanical Engineering and his B.S. in Engineering and Applied Science, all from the California Institute of Technology.

Elisa Hebb
Elisa Hebb joined Endologix in August 2018 with more than twenty years of success in Clinical Research and Regulatory Affairs. She has led the development and execution of global clinical studies for both Class II and Class III medical devices in addition to leading regulatory strategies, and submissions for US and international agencies. Elisa comes to us from Spirox where she was responsible for clinical and regulatory and was the Compliance Officer. Previously, Elisa was the Senior Director of Global Clinical Affairs and Clinical Development for Philips Volcano. Prior vice presidential roles held by Elisa include Atheromed, Crux Biomedical and Apneon. Prior experience is largely in the vascular and electrophysiology with such companies as Boston Scientific, Vascular Architects and ACS. Elisa earned her Bachelor’s degree from UC Berkeley.
valerie tansley

Valerie LS Tansley joined Endologix in March 2014. Valerie has over 30 years of experience in the life sciences industry, starting her career in R&D at Johnson & Johnson developing DNA-based diagnostic test kits. This was followed by 26 years at Edwards Lifesciences (previously a Baxter Healthcare company), a global leader in patient-focused innovations, where she held positions in the Critical Care division with increasing responsibility across a wide variety of functions, including Baxter corporate business development, marketing, continuous improvement, supply chain, R&D, leading a divesture team, and leading the new product development project management office. Upon joining Endologix, Valerie led the Nellix commercialization/PMA efforts, then revitalized our Lean/Six Sigma program, including leading global Lean and Black Belt projects. Most recently she was a Sr. Director in Human Resources responsible for the Irvine site, talent acquisition, performance management, and HR Administration teams. Valerie has a proven track record of using her broad functional experience to build high performance teams and deliver on objectives. Valerie earned her B.A. in Biochemistry/Molecular Biology from the University of California, Santa Barbara and her M.B.A. from Pepperdine University.

brian chambless headshot
Brian Chambless joined in October 2005. He has more than 20 years of sales and leadership experience, including 18 years in the vascular/endovascular space. During his tenure with Endologix, he held sales management positions with increasing responsibilities, serving the last seven years as Director of Sales. Prior to joining Endologix, Brian spent five years at Boston Scientific in the Peripheral Vascular division. Expertise include sales, marketing, training, commercial strategy and sales team development in both the large company and start up environment. Brian holds a B.S. in Business Management from the University of Alabama.
Dan Lemaitre

Dan Lemaitre most recently served as the President and CEO of Direct Flow Medical. Previously, Mr. Lemaitre was the CEO of CoreValve, one of the early pioneers in transcatheter aortic valves.  By 2009 revenue were at a $100 million annualized end market run rate.  Dan led negotiations that resulted in the sale of CoreValve to Medtronic in a transaction valued at $800 million.

Prior to joining CoreValve, Mr. Lemaitre was a Senior Vice President at Medtronic where he headed-up strategic planning and corporate development.  Dan was also a member of Medtronic’s executive and operating committees.    

In 2012 Dan was part of an investor syndicate that took private a $250 million division of a major orthopedic company and served as its initial Chairman.   He is also on the board of Globus Medical  (NYSE: GMED) one of the fastest growing spinal companies with revenue of ~$600 million per annum.  Dan serves on the Globus audit and compensation committees.

Earlier in his career Dan spent 28 years in the medical device field as an investment analyst.  He began his career as a buy-side analyst in 1978 working at National City Bank in Cleveland and later, Standish Ayer & Wood in Boston.  His sell-side career included 18 years with Cowen & Company, where he was a managing director and led the health care research team.  In 1999, Dan moved his team to Merrill Lynch where he headed-up the medical technology effort for six years.  During his Wall Street tenure, Dan was named to Institutional Investor’s All American research team for 19 consecutive years, capturing first place honors 8 times as the top-ranked medical device analyst in the country. 

Dan has a BA in Economics (1976) from Bethany College (West Virginia) and an MBA (1978) from Bowling Green State University in Ohio.  He earned a Chartered Financial Analyst (CFA) in 1982.   

Ms. Jane E. Kiernan has served on our board of directors since 2020. Ms. Kiernan has more than 30 years of executive and management leadership with both public and private companies in the healthcare sector. She has financial experience in strategy, mergers & acquisitions, and scaling for global growth. Ms. Kiernan currently serves on the board of directors of Axonics Modulation Technologies. She is a co-founder of K2 Biotechnology Ventures, an investment firm engaged in developing and commercializing portfolios of university and medical center innovations in partnership with venture capital, healthcare corporations and philanthropic healthcare foundation partners. She previously served on the board of directors of American Medical Systems from 2006 to 2011, when it was acquired by Endo Pharmaceuticals. In 2010, Ms. Kiernan became Chief Executive Officer and President of Salter Labs, a privately held medical device company which produces respiratory and anesthesia single-use, disposable products. From 2001 to 2010, she held executive and general management positions with Baxter Healthcare Corporation and prior to 2001, she served in corporate and line management roles in finance, strategy, marketing, and operations with both Baxter Corporation and Allegiance Healthcare Corporation. As a community leader, recently, Ms. Kiernan served on the board of directors for Ryan Banks Academy, which will be the first urban boarding school in Chicago, and she served as Committee Chair and on the board of directors of the American Red Cross of Greater Chicago. In addition, she previously served as President of the Healthcare Businesswomen’s Association (HBA), Chicago Chapter. Ms. Kiernan holds a B.S. in business from Southern Methodist University in Dallas, Texas.
Leslie Norwalk

Ms. Leslie Norwalk has served on our board of directors since 2015. Ms. Norwalk currently serves as a Strategic Advisor and Strategic Counsel to the law firm Epstein Becker & Green, P.C., healthcare and life science consultancy EBG Advisors, Inc., and legislative and regulatory consultancy National Health Advisors. Ms. Norwalk is also an Operating Partner at Enhanced Equity Fund, L.P. and serves as an Advisor to Warburg Pincus LLC, and Peloton Equity. Previously, Ms. Norwalk served the Bush Administration as the Acting Administrator for the Centers for Medicare & Medicaid Services, where she managed the day-to-day operations of Medicare, Medicaid, State Child Health Insurance Programs, Survey and Certification of health care facilities and other federal health care initiatives. For four years prior to that, she was the agency’s Deputy Administrator, responsible for the implementation of the changes made under the Medicare Modernization Act, including the Medicare Prescription Drug Benefit. Prior to serving the Bush Administration, Ms. Norwalk practiced law in the Washington, D.C. office of Epstein Becker & Green, P.C. where she advised clients on a variety of health policy matters. She also served in the first Bush administration in the White House Office of Presidential Personnel, and the Office of the U.S. Trade Representative. Ms. Norwalk also serves as Member of International Advisory Council at APCO Worldwide Inc. She earned a J.D. degree from the George Mason University School of Law and a bachelor’s degree, cum laude, in Economics and International Relations from Wellesley College.

Gregory Waller

Gregory D. Waller has served on our board of directors since November 2003. Mr. Waller also serves on the board of Sunshine Heart Corporation, a publicly traded company, as Audit Committee Chairman and was the Chief Financial Officer of Ulthera Corporation, a privately held company that sells an ultrasound device used for non-invasive brow lifts from October of 2011 until its acquisition by Merz GMBH. He retired from Ulthera in April of 2015. From March 2006 until April 2011, Mr. Waller was Chief Financial Officer of Universal Building Products, a manufacturer of concrete construction accessories. Previous to that, Mr. Waller has been in retirement except for board directorships. Mr. Waller served as Vice President-Finance, Chief Financial Officer and Treasurer of Sybron Dental Specialties, Inc., a manufacturer and marketer of consumable dental products, from August 1993 until his retirement in May 2005 and was formerly the Vice President and Treasurer of Kerr, Ormco Corporation, and Metrex. Mr. Waller joined Ormco Corporation in December 1980 as Vice President and Controller and served as Vice President of Kerr European Operations from July 1989 to August 1993. Mr. Waller has an M.B.A. with a concentration in Accounting from California State University, Fullerton. Mr. Waller also served on the board of directors and audit committee of Cardiogenesis Corporation, a publicly-traded company until its acquisition by Cryolife in 2011. Mr. Waller also served on the boards of directors of Alsius Corporation, a publicly-traded company, from June 2007 to September 2009 until its acquisition by Zoll, Biolase Technology, Inc., a publicly-traded company, from October 2009 to August 2010, Clarient, Inc., a publicly-traded company which was acquired by General Electric Company on December 22, 2010, and SenoRx, Inc., a publicly-traded company which was acquired by C.R. Bard, Inc. on July 6, 2010.

Thomas Wilder

Thomas Wilder has served on our board of directors since May 2010. He currently also serves on the board of Penumbra Inc. (PEN), a global interventional therapies company that designs, develops, manufactures and markets innovative medical devices, and on the board of Benvenue Medical Inc., a privately-held medical device company focused on the design, manufacture, and marketing of cutting edge products for the rapidly growing minimally invasive spinal surgery market.  From February 2010, Mr. Wilder served as President and Chief Executive Officer of Sequent Medical, Inc., until it was acquired by Terumo Corporation in July 2016.  From May 2009 to January 2010, Mr. Wilder consulted with several medical device companies. From April 2006 to April 2009, Mr. Wilder served as President and Chief Executive Officer of Photothera, Inc. From 2002 through January 2006, Mr. Wilder served at Micro Therapeutics, Inc. (MTIX) as President and Chief Executive Officer. Following the merger of Micro Therapeutics, Inc. into ev3 Inc. in January 2006, Mr. Wilder served as President, ev3 Neurovascular until April 2006. From 1991 to 2002, Mr. Wilder served in various roles for Medtronic, Inc. Mr. Wilder has a B.A. in Economics from Stanford University and an M.B.A. from Northwestern University's J.L. Kellogg Graduate School of Management.

Thomas Zenty

Thomas F. Zenty, III has served on our board of directors since May 2013. He is currently the President and Chief Executive Officer of University Hospitals Health System, Inc., Cleveland, OH.  Previously, Mr. Zenty held various executive positions at Cedars-Sinai Health System, St. Josephs Medical Center, a division of Catholic Health Care West, Franciscan Health System of New Jersey and St. Mary Hospital, Connecticut.  Mr. Zenty is Chairman of the Board of Western Reserve Assurance Company, Ltd. SPC, a privately-held insurance company and chairs The Coalition to Protect American’s Health Care.  Mr. Zenty is a past board member of the American Hospital Association and has also served on the board of directors of Nationwide Financial Services and Amerimed. Mr. Zenty has held several academic positions with prestigious universities, including his current position as Adjunct Professor, Banking & Finance at Case Western Reserve University.  He received a Master’s degree in Public Administration from New York University, a Master’s degree in Hospital Administration from Xavier University, and a Bachelor’s degree in Health Planning from Pennsylvania State University.

John Onopchenko

John Onopchenko became the Chief Executive Officer in May 2018 after joining us in October 2017 as Chief Operating Officer. With almost thirty years of experience in medical devices, John most recently served as Executive Vice President for Acutus Medical. In 2013, after a decade on the Board of Directors of Volcano Corporation, John stepped off the Board, joined the leadership team and ultimately became the company’s Chief Operating Officer. After Phillips acquired Volcano in March 2015, John was retained by Philips as Senior Vice President and Head of Therapy Strategy. Prior to Volcano John, was a founder and Managing Director of Synergy Life Partners, a medical device venture capital firm. The previous 20 years of John’s career included increasing leadership responsibilities at Johnson & Johnson and GE Healthcare. John received his Bachelors of Science degree from Ursinus College and his MBA from the University of Chicago.